Janux therapeutics provides business update and reports fourth quarter and full year 2021 financial results

San diego--(business wire)--janux therapeutics, inc. (nasdaq: janx) (janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its tumor activated t cell engager (tractr) and tumor activated immunomodulator (tracir) platforms, today reported financial results for the fourth quarter and full year ended december 31, 2021 and provided a business update. “janux made great strides in 2021 as we transitioned to a public company
JANX Ratings Summary
JANX Quant Ranking